Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 28;64(9):2478–2488. doi: 10.1007/s10620-019-05594-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PMC Copyright notice

Fig. 2 — Drug access under medical coverage for ulcerative colitis and Crohn’s disease. ^aApproximately 7% and 8% of lives had unknown coverage under medical benefit in UC and CD, respectively. ^bApproximately 16% and 7% of lives had unknown coverage under pharmacy benefit in UC and CD, respectively. ^cThe calculated percentage of covered lives excluded all unknown lives. ^dTofacitinib has a large percentage of unknown lives (~ 25%), primarily because it was only approved for UC in May 2018. Therefore, this may result in overinflection of the “No Biologic” coverage. CD, Crohn’s disease; MMIT, Managed Markets Insight and Technology; UC, ulcerative colitis

Source: MMIT, December 18, 2018